29 July 2025 in Multiple Sclerosis and Related Disorders
The 2024 revision of the McDonald criteria introduces specific recommendations for diagnosing late-onset multiple sclerosis (LOMS). One of the following criteria must be met: spinal cord lesions, positive cerebrospinal fluid (CSF) findings, or fulfilment of the Select-6 criteria (i.e., six or more central vein signs on brain magnetic resonance imaging (MRI)). To evaluate the sensitivity of the 2024 McDonald criteria in patients with LOMS and to identify the most sensitive diagnostic test. This cross-sectional, observational, retrospective study included patients diagnosed with LOMS (onset ≥50 years of age) who were followed at the Multiple Sclerosis Clinic of Bellvitge University Hospital. Clinical records, MRI scans, and CSF analyses were reviewed to assess the presence of spinal cord lesions, central vein signs and oligoclonal bands (OCBs). The sensitivity of the 2024 recommended LOMS criteria was analysed. 115 patients met at least one of the proposed 2024 LOMS diagnostic criteria, resulting in a sensitivity of 100 %. Of these, 10.4 % fulfilled all three criteria, 52.1 % met two criteria (most commonly OCBs and spinal lesions). The remaining 37.4 % met only one: 53.5 % had spinal lesions, 46.5 % were positive for OCBs, and none met only the Select-6 criterion. The difference between the proportions meeting the OCB and spinal cord lesion criteria was not statistically significant (p = 0.581), but both were significantly more common than meeting the Select-6 criterion (p < 0.001). The 2024 McDonald criteria maintain high sensitivity for diagnosing LOMS. CSF analysis and spinal MRI are the most valuable tools, whereas the Select-6 criteria exhibited a lower diagnostic value.
17 September 2024 in Neurological Sciences
Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.
1 February 2016 in Journal of Neuroimmunology
1 November 2011 in Value in Health
5 November 2025 in Journal of Neurology
Background: The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated. Methods: Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed. Results: Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment. Conclusion: The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.
3 November 2026 in BMC Neurology
The aetiologic diagnosis of longitudinally extensive spinal cord lesions (LESCL) is challenging because its broad differential. Early recognition of diagno